NGNE logo

Neurogene (NGNE)

Profile

Full Name

Neurogene Inc.

Ticker Symbol

NGNE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

March 7, 2014

Indexes

Not included

Website

http://www.neurogene.com

Employees

107

Key Details

Price

$11.00(+22.63%)

Market cap

$164.23M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$925.00K

Annual EPS

-$4.28(+94.20% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$11.00
NGNE price is $11.00

30-Day Relative Volume

1.99
NGNE 30-day relative volume is 1.99

Price Performance

Price Most recent change

+22.63%
NGNE price was up +22.63% on Apr 11, 2025

Price YTD change

-51.88%
NGNE price is down -51.88% since January 1st

Price 1-year change

-71.3%
NGNE price is down -71.3% year-on-year

Price 3-year change

-66.26%
NGNE price is down -66.26% over the past 3 years

Price Range

Price All-time high

$1115.00
NGNE price is currently -99.01% below its historical high of $1115.00

Price 3-year low

$6.88
NGNE price is currently +60.00% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$164.23M
NGNE market capitalization is $164.23 million

Market cap 3-year change

-
NGNE market capitalization 3-year change is unknown

Market cap All-time high

$1.04B
NGNE market capitalization is currently -84.20% below its historical high of $1.04 billion

Market cap sector rank

55.38%
NGNE market capitalization is higher than 55.38% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+16.08%
NGNE shares outstanding is up +16.08% year-on-year

Shares Outstanding 3-Year Change

-
NGNE shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.72
NGNE beta is 1.72

200-day SMA

$30.46
NGNE price is currently -63.89% below its 200-day simple moving average

50-day SMA

$15.57
NGNE price is currently -29.36% below its 50-day simple moving average

RSI

43.25
NGNE 14-day relative strength index is 43.25

Volume

1.99
NGNE 30-day relative volume is 1.99

ATR

$1.61
NGNE average true range is $1.61

10-day Historical Volatility

240.12%
NGNE 10-day historical volatility is 240.12%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$925.00K
NGNE annual revenue is $925.00 thousand

Revenue Analysts estimate

-
NGNE annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
NGNE annual revenue 1-year change is unknown

Revenue Sector rank

11.87%
NGNE annual revenue is higher than 11.87% of companies in Healthcare sector

EPS

EPS

-$4.28
NGNE annual earnings per share is -$4.28

EPS Analysts estimate

-$3.70
NGNE annual earnings per share is currently +15.68% higher than the consensus analysts' forecast

EPS 1-year change

+94.2%
NGNE annual earnings per share is up +94.2% year-on-year

EPS Sector rank

21.8%
NGNE annual earnings per share is higher than 21.8% of companies in Healthcare sector

Profit

Gross profit

-
NGNE annual gross profit value is unknown

Gross margin

-
NGNE annual gross profit margin value is unknown

Operating profit

-$82.61M
NGNE annual operating income is -$82.61 million

Operating margin

-8930.27%
NGNE annual operating profit margin is -8930.27%

Net income

-$75.14M
NGNE annual net profit is -$75.14 million

Net margin

-8123.68%
NGNE annual net profit margin is -8123.68%

Expenses

Total expenses

$83.53M
NGNE annual total expenses is $83.53 million

Operating expenses

$83.53M
NGNE annual total operating expenses is $83.53 million

Cost of goods sold

-
NGNE annual cost of goods sold value is unknown

Selling, general & administrative expenses

$22.61M
NGNE annual SGA is $22.61 million

Depreciation and amortization

$3.25M
NGNE annual depreciation & amortization is $3.25 million

Interest expense

$12.00K
NGNE annual interest expense is $12.00 thousand

Income tax

-
NGNE annual income tax value is unknown

EBIT & EBITDA

EBIT

-$75.13M
NGNE annual earnings before interest & taxes is -$75.13 million

EBITDA

-$71.89M
NGNE annual EBITDA is -$71.89 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$335.73M
NGNE annual total assets is $335.73 million

Non current assets

$19.81M
NGNE annual long term assets is $19.81 million

Current assets

$315.92M
NGNE annual total current assets is $315.92 million

Cash and cash equivalents

$136.59M
NGNE annual cash & cash equivalents is $136.59 million

Accounts receivable

-
NGNE annual accounts receivable value is unknown

Inventory

-
NGNE annual inventory value is unknown

Liabilities

Total liabilities

$25.36M
NGNE annual total liabilities is $25.36 million

Long term liabilities

$10.20M
NGNE annual total long term liabilities is $10.20 million

Current liabilities

$15.16M
NGNE annual total current liabilities is $15.16 million

Accounts payable

$1.34M
NGNE annual accounts payable is $1.34 million

Debt

Total debt

$14.24M
NGNE annual total debt is $14.24 million

Total debt 1-year change

-12.41%
NGNE annual total debt is down -12.41% year-on-year

Long term debt

$10.15M
NGNE annual long term debt is $10.15 million

Short term debt

$4.09M
NGNE annual short term debt is $4.09 million

Equity & Capital

Shareholders equity

$310.38M
NGNE annual stockholders equity is $310.38 million

Book value

$310.38M
NGNE annual book value is $310.38 million

Retained earnings

-$262.30M
NGNE annual retained earnings is -$262.30 million

Working capital

$300.77M
NGNE annual working capital is $300.77 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$70.60M
NGNE annual cash flow from operations is -$70.60 million

Cash from operations 1-year change

-37.3%
NGNE annual cash flow from operations is down -37.3% year-on-year

Cash from investing

-$125.26M
NGNE annual cash flow from investing activities is -$125.26 million

Cash from investing 1-year change

-588.59%
NGNE annual cash flow from investing activities is down -588.59% year-on-year

Cash from financing

$184.07M
NGNE annual cash flow from financing activities is $184.07 million

Cash from financing 1-year change

+99.03%
NGNE annual cash flow from financing activities is up +99.03% year-on-year

CAPEX

CAPEX

$808.00K
NGNE annual capital expenditures is $808.00 thousand

CAPEX 1-year change

-
NGNE annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$71.41M
NGNE annual free cash flow is -$71.41 million

Free cash flow 1-year change

-38.01%
NGNE annual free cash flow is down -38.01% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
NGNE annual gross profit margin value is unknown

Operating margin

-8930.27%
NGNE annual operating profit margin is -8930.27%

Net margin

-8123.68%
NGNE annual net profit margin is -8123.68%

ROA & ROE

ROA

-22.38%
NGNE annual return on assets is -22.38%

ROE

-30.28%
NGNE annual return on equity is -30.28%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
NGNE price to earnings ratio value is unknown

PE ratio Sector rank

-
NGNE price to earnings ratio is unknown

PB Ratio

PB ratio

0.53
NGNE price to book ratio is 0.53

PB ratio Sector rank

31%
NGNE price to book ratio is higher than 31% of companies in Healthcare sector

PS Ratio

PS ratio

-
NGNE price to sales ratio value is unknown

PS ratio Sector rank

-
NGNE price to sales ratio is unknown

Enterprise value

Enterprise value

$41.88M
NGNE enterprise value is $41.88 million

Enterprise value Sector rank

40.07%
NGNE enterprise value is higher than 40.07% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.58
NGNE EV/EBITDA is -0.58

EV/EBITDA Sector rank

49.74%
NGNE EV/EBITDA is higher than 49.74% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

20.84
NGNE annual current ratio is 20.84

Quick ratio

-
NGNE annual quick ratio value is unknown

Leverage

Debt to equity

0.00
NGNE annual debt to equity ratio is 0.00

Interest coverage ratio

-6261.00
NGNE annual interest coverage ratio is -6261.00

Risk & Stability

Piotroski F-Score

-
NGNE piotroski f-score value is unknown

Altman Z-Score

3.13
NGNE altman z-score is 3.13

Analyst ratings

Recent major analysts updates

Mar 25, 25 HC Wainwright & Co.
Buy
Nov 25, 24 HC Wainwright & Co.
Buy
Nov 20, 24 BMO Capital
Outperform
Nov 19, 24 HC Wainwright & Co.
Buy
Nov 12, 24 Stifel
Buy
Nov 12, 24 Leerink Partners
Outperform
Nov 12, 24 HC Wainwright & Co.
Buy
Nov 12, 24 Baird
Outperform
Nov 12, 24 BMO Capital
Outperform
Aug 12, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

THRD logo
Third Harmonic Bio (THRD)
HITI logo
High Tide (HITI)
CRDF logo
Cardiff Oncology (CRDF)
DSGN logo
Design Therapeutics (DSGN)
ANNX logo
Annexon (ANNX)
PROC logo
Procaps Group SA (PROC)
CVRX logo
CVRx (CVRX)
SGMO logo
Sangamo Therapeutics (SGMO)
INBX logo
Inhibrx Biosciences (INBX)
  • What is the ticker symbol for Neurogene?
  • Does Neurogene pay dividends?
  • What sector is Neurogene in?
  • What industry is Neurogene in?
  • What country is Neurogene based in?
  • When did Neurogene go public?
  • Is Neurogene in the S&P 500?
  • Is Neurogene in the NASDAQ 100?
  • Is Neurogene in the Dow Jones?
  • When was Neurogene's last earnings report?
  • When does Neurogene report earnings?
  • Should I buy Neurogene stock now?

What is the ticker symbol for Neurogene?

The ticker symbol for Neurogene is NASDAQ:NGNE

Does Neurogene pay dividends?

No, Neurogene does not pay dividends

What sector is Neurogene in?

Neurogene is in the Healthcare sector

What industry is Neurogene in?

Neurogene is in the Biotechnology industry

What country is Neurogene based in?

Neurogene is headquartered in United States

When did Neurogene go public?

Neurogene's initial public offering (IPO) was on March 7, 2014

Is Neurogene in the S&P 500?

No, Neurogene is not included in the S&P 500 index

Is Neurogene in the NASDAQ 100?

No, Neurogene is not included in the NASDAQ 100 index

Is Neurogene in the Dow Jones?

No, Neurogene is not included in the Dow Jones index

When was Neurogene's last earnings report?

Neurogene's most recent earnings report was on Mar 24, 2025

When does Neurogene report earnings?

The next expected earnings date for Neurogene is May 9, 2025

Should I buy Neurogene stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page